For the quarter ended December 2025, Collegium Pharmaceutical (COLL) reported revenue of $205.45 million, up 12.9% over the same period last year. EPS came in at $2.04, compared to $1.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $208.65 million, representing a surprise of -1.53%. The company delivered an EPS surprise of -6.99%, with the consensus EPS estimate being $2.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Chief Commercial Officer Scott Dreyer said Jornay delivered record prescription volume in both the fourth quarter and full year 2025. In the fourth quarter, more than 200,000 prescriptions were written, up 16% year-over-year, and more than 760,000 prescriptions were written in 2025, up 20%. Dreyer added that average weekly prescriptions increased to approximately 16,600 in December from about 13,800 in July, and he said momentum continued into January at approximately 16,800 weekly prescriptions despite typ ...

Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorColleen Tupper - CFOIan Karp - Head of Investor RelationsJeevan Larson - Equity Research AssociateScott Dreyer - Chief Commercial OfficerVikram Karnani - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystOperatorGreetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings co ...

Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorColleen Tupper - CFOIan Karp - Head of Investor RelationsJeevan Larson - Equity Research AssociateScott Dreyer - Chief Commercial OfficerVikram Karnani - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystOperatorGreetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings co ...

Collegium Pharmaceutical (NasdaqGS:COLL) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker5Greetings! Welcome to the Collegium Pharmaceutical fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during this conference call, please press star zero on your telephone keypad. Please note, this conference call is being recorded. I ...

Core Insights - The article discusses the positive momentum and potential upside for Collegium Pharmaceutical (COLL) following its acquisition of BDSI, highlighting the company's growth trajectory since late 2022 [1]. Company Overview - Collegium Pharmaceutical is positioned in the healthcare sector, focusing on innovative therapies and pharmaceuticals, particularly in the pain management space with products like Xtampza ER [1]. Investment Strategy - The analysis emphasizes the importance of identifying companies with breakthrough therapies and potential acquisition catalysts, which is a key focus for investors in the biotech and pharmaceutical industries [1].

Core Insights - Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $209.4 million, representing a 31% increase year-over-year [1][11] - The company raised its full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million [1][8] - The company ended Q3 2025 with cash, cash equivalents, and marketable securities totaling $285.9 million [1] ADHD Business Highlights - Jornay PM net revenue reached a record $41.8 million, with prescriptions growing by 20% year-over-year [1][7] - The number of healthcare providers prescribing Jornay PM increased by 22% year-over-year, reaching an all-time high of 27,700 [7] Pain Portfolio Highlights - The pain portfolio generated record net revenue of $167.6 million, up 11% year-over-year, with all three core products showing growth [1][7] - Belbuca net revenue was $58.3 million, up 10% year-over-year, while Xtampza ER net revenue was $50.5 million, up 2% year-over-year [7] - Nucynta Franchise net revenue increased by 21% year-over-year, totaling $54.8 million [7] Financial Results - GAAP net income for Q3 2025 was $31.5 million, with GAAP earnings per share of $1.00 (basic) and $0.84 (diluted) [11][29] - Adjusted EBITDA for the quarter was $133.0 million, a 27% increase from the previous year [11][32] - The company generated $78.4 million in cash from operations during the quarter [11] Corporate Updates - The company has authorized a new share repurchase program to buy back up to $150 million of common stock through December 31, 2026 [10] - Collegium celebrated its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market [10]

Core Insights - Collegium Pharmaceutical reported $188 million in revenue for the quarter ended June 2025, marking a year-over-year increase of 29.4% and an EPS of $1.68 compared to $1.62 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $180.38 million by 4.23%, and the EPS also surpassed the consensus estimate of $1.62 by 3.7% [1] Revenue Breakdown - Total product revenues for Belbuca were $52.6 million, slightly below the average estimate of $54.94 million, reflecting a year-over-year change of +0.8% [4] - Xtampza ER generated $52.61 million, exceeding the average estimate of $48.28 million, with an 18% increase compared to the previous year [4] - Jornay PM reported revenues of $32.63 million, slightly above the average estimate of $32.23 million [4] - Nucynta achieved $46.45 million in revenues, surpassing the average estimate of $43.31 million, representing a year-over-year change of +4.4% [4] - Symproic revenues were $3.72 million, exceeding the average estimate of $3.45 million, but showing a decline of 7.7% year-over-year [4] Stock Performance - Collegium Pharmaceutical's shares have returned -8.1% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Financial Performance - The company reported record revenue growth of 29% year over year, with adjusted EBITDA increasing by 9% year over year [6][21][22] - Net product revenues reached $188 million, with Jornay PM contributing $32.6 million, BELBUCA at $52.6 million (up 1%), Xtampza at $52.6 million (up 18%), and Nucynta franchise at $46.4 million (up 4%) [22][23] - GAAP net income was $12 million, down from $19.6 million in the prior year, while non-GAAP adjusted earnings per share increased to $1.68 from $1.62 [23][24] Business Lines Performance - Jornay PM prescriptions grew by 23% year over year, with record quarterly revenues of $32.6 million [6][22] - The pain portfolio generated record revenues of $155.4 million, up 7% year over year, with all three core pain medicines showing growth [6][18] Market Data - Jornay PM's market share in the long-acting branded methylphenidate market grew to 23%, up 7.6 percentage points year over year [15] - The company expanded its prescriber base for Jornay PM to over 26,000, a 23% increase compared to the previous year [15][35] Company Strategy and Industry Competition - The company aims to build a diversified biopharmaceutical portfolio, focusing on significant growth for Jornay PM and maximizing the pain portfolio [4][9] - The company is committed to strategic capital deployment, including share repurchases and business development opportunities [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on financial and strategic commitments, raising 2025 revenue guidance to approximately 19% growth year over year [8][28] - The company is focused on increasing awareness of Jornay PM among healthcare providers and patients, particularly in the adult ADHD market [12][17] Other Important Information - The company completed a $25 million accelerated share repurchase program and announced a new $150 million share repurchase program [7][26] - The company ended the quarter with $222.2 million in cash and cash equivalents, while reducing debt by $16.1 million [10][24] Q&A Session Summary Question: What is the target goal for additional prescribers for Jornay PM by year-end? - Management indicated that there is no specific goal for prescribers but expects continued growth in prescriber breadth [34][35] Question: What are the specific levers for growth in the third quarter? - Management highlighted the importance of raising awareness among healthcare providers and patients to drive prescriptions [51] Question: Any updates on generic competition for the pain portfolio? - Management noted that there are no immediate threats from generics due to regulatory and manufacturing barriers [53][56] Question: How does the company view potential business development opportunities? - Management stated a commitment to disciplined assessment of potential opportunities, focusing on commercial-ready assets [60][61]

Summary of Collegium Pharmaceutical (COLL) Conference Call Company Overview - Collegium Pharmaceuticals is focused on building a diversified biopharmaceutical company, primarily addressing chronic pain and ADHD [2][3] - The company generated $631 million in net sales in 2024, with an expected growth of 18% to $743 million in 2025 [3][9] Product Portfolio - The company has five marketed products, including: - **Jornay PM**: $100 million in net sales in 2024, expected to exceed $135 million in 2025. It is the only ADHD medicine with once-daily evening dosing [5][6] - **BELBUCA**: $211 million in net sales in 2024, a long-acting opioid using buprenorphine buccal film technology [7] - **Xtampza ER**: $191 million in net sales in 2024, an extended-release oxycodone with abuse deterrent technology [8] - **Nucynta Franchise**: $177 million in net sales in 2024, treating severe and persistent pain as well as neuropathic pain [8] Financial Performance - Expected net revenues for 2025 are between $735 million and $750 million, indicating an 18% year-over-year growth [9] - Adjusted EBITDA is projected to be between $435 million and $450 million, representing a 10% year-over-year growth [10] - Adjusted operating expenses are expected to grow by 49% year-over-year due to the acquisition of Ionshore Therapeutics [10] Revenue Durability - The company has a strong expectation of revenue durability, with projected exclusivity for Xtampza ER through September 2033 and BELBUCA until January 2027 [14][15] - No generic competitors have satisfied all criteria to launch future generics, which supports the durability of the pain portfolio [17] Recent Business Highlights - In Q1 2025, the company achieved $177 million in net sales, a 23% increase from 2024 [18] - Cash from operations was over $55 million, with a leverage ratio of 1.5 net debt over EBITDA, expected to decrease to less than 1 by the end of 2025 [19] - A share repurchase program of $25 million was announced in May 2025 [19] Growth Strategies - The company is investing in Jornay PM to maximize growth and has expanded its sales team from 125 to 180 representatives [21][22] - Marketing programs are being implemented to raise awareness among caregivers and patients, aligning with the back-to-school season [23] Competitive Positioning - Collegium is positioned uniquely among biopharmaceutical peers with a robust revenue profile and double-digit growth [25] - The company has a strong cash generation profile and a history of returning value to shareholders, having repurchased $222 million in shares since 2021 [26][27] - The majority of its medicines are sourced and sold in the US, making them largely immune to tariffs and pricing pressures [28] Conclusion - Collegium Pharmaceuticals is well-positioned for continued growth, with a strong focus on revenue generation, profitability, and disciplined capital deployment strategies [28]